Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Myriad Genetics (MYGN) Current Leases (2019 - 2026)

Myriad Genetics has reported Current Leases over the past 7 years, most recently at $6.9 million for Q4 2025.

  • Quarterly Current Leases fell 46.09% to $6.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.9 million through Dec 2025, down 46.09% year-over-year, with the annual reading at $6.9 million for FY2025, 46.09% down from the prior year.
  • Current Leases was $6.9 million for Q4 2025 at Myriad Genetics, down from $7.9 million in the prior quarter.
  • Over five years, Current Leases peaked at $17.8 million in Q3 2023 and troughed at $6.9 million in Q4 2025.
  • The 5-year median for Current Leases is $13.4 million (2022), against an average of $13.1 million.
  • Year-over-year, Current Leases increased 27.82% in 2023 and then crashed 46.09% in 2025.
  • A 5-year view of Current Leases shows it stood at $13.0 million in 2021, then grew by 8.46% to $14.1 million in 2022, then increased by 14.89% to $16.2 million in 2023, then dropped by 20.99% to $12.8 million in 2024, then crashed by 46.09% to $6.9 million in 2025.
  • Per Business Quant, the three most recent readings for MYGN's Current Leases are $6.9 million (Q4 2025), $7.9 million (Q3 2025), and $9.0 million (Q2 2025).